Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2007 1
2008 2
2009 3
2011 3
2012 4
2013 7
2014 10
2015 12
2016 18
2017 12
2018 9
2019 12
2020 10
2021 18
2022 6
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study.
Bianchi A, De Rimini ML, Sciuto R, Annovazzi A, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Scarlattei M, Baldari G, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, Evangelista L. Bianchi A, et al. Cancer Biother Radiopharm. 2023 May;38(4):256-267. doi: 10.1089/cbr.2022.0092. Epub 2023 Apr 25. Cancer Biother Radiopharm. 2023. PMID: 37098169
An optimized SpCas9 high-fidelity variant for direct protein delivery.
Pedrazzoli E, Bianchi A, Umbach A, Amistadi S, Brusson M, Frati G, Ciciani M, Badowska KA, Arosio D, Miccio A, Cereseto A, Casini A. Pedrazzoli E, et al. Among authors: bianchi a. Mol Ther. 2023 Jul 5;31(7):2257-2265. doi: 10.1016/j.ymthe.2023.03.007. Epub 2023 Mar 10. Mol Ther. 2023. PMID: 36905119 Free article.
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors.
Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Cervati V, Ledda RE, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, De Rimini ML. Evangelista L, et al. Among authors: bianchi a. Cancers (Basel). 2023 Jan 31;15(3):878. doi: 10.3390/cancers15030878. Cancers (Basel). 2023. PMID: 36765835 Free PMC article.
Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
Biggi A, Chauvie S, Fallanca F, Guerra L, Bergesio F, Menga M, Bianchi A, Gregianin M, Chiaravalloti A, Schillaci O, Pavoni C, Patti C, Picardi M, Romano A, Schiavotto C, Sorasio R, Viviani S, La Nasa G, Trentin L, Rambaldi A, Gallamini A. Biggi A, et al. Among authors: bianchi a. Hematol Oncol. 2023 Aug;41(3):415-423. doi: 10.1002/hon.3117. Epub 2023 Jan 4. Hematol Oncol. 2023. PMID: 36534947 Clinical Trial.
119 results